SCY-078 (MK-3118)

Title Content type
Discovery of Plant Sterol-Derived Gamma-Secretase Modulators by Molecular Editing of a Triterpenoid Glycoside (click for details)
Clone of Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. (click for details)
Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates. (click for details)
Latest information on SCY-078 (MK-3118; enfumafungin) from Scynexis (click for details)
Evaluation of the antifungal activity of SCY-078 in combination with other antifungals against Aspergillus strains (click for details)
A prospective, phase 2, multicentre, open-label, randomized, comparative study to estimate the safety, tolerability, pharmacokinetics, and efficacy of oral SCY-078 vsstandard-of-care following initial intravenous echinocandin therapy in the treatment of.. (click for details)
A prospective, phase 2, multicentre, open-label, randomized, comparative study to estimate the safety, tolerability, pharmacokinetics, and efficacy of oral SCY-078 vsstandard-of-care following initial intravenous echinocandin therapy in the treatment of.. (click for details)
Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis. (click for details)
Scynexis (SCYX) Announces Results from Two Completed SCY-078 Phase 2s; Closes $15 Term Loan (click for details)
Safety and Efficacy of Oral SCY-078 vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis (click for details)

Pages

Subscribe to SCY-078 (MK-3118)